Webinar | Is Your Packaging PPWR Ready? Register Here

Home / Case Studies / FTO Strategy That Uncovered Hidden Risks for Denosumab Launch

FTO Strategy That Uncovered Hidden Risks for Denosumab Launch

Revealing Hidden Antibody Formulation Risks via Composition of Matter Patent Linkage

Value Delivered

The investigation enabled the client to uncover a hidden third-party patent that indirectly covered Denosumab formulations by referencing the COM patent. Identifying this risk early protected substantial investment and prevented potential litigation delays in a market valued at over $3 billion annually. The findings provided clear strategic boundaries for formulation design and helped the client’s R&D team make informed decisions.

Problems Solved

A leading biologics developer preparing to commercialize a Denosumab-based therapy faced a significant challenge typical in antibody development: navigating a dense patent landscape. Standard Freedom-to-Operate (FTO), including Purple Book analysis and sequence-based searches on platforms such as Patsnap Bio, was initially performed.

These efforts identified several publications directly claiming denosumab antibodies, and functional class-based, composition-of-matter (COM) patents like (WO 03/002713) covering Denosumab’s sequence. However, these conventional methods failed to detect indirect blocking patents, particularly those that did not mention Denosumab or its sequence yet restricted its manufacture or formulation.

Missing out on such publications would have exposed the company to potential infringement risks and late-stage setbacks in its R&D cycle.

Solution Offered

A comprehensive, multi-layered FTO investigation was conducted. Deeper analysis focused on patents that directly referenced this COM patent within their specifications. This search uncovered a formulation patent broadly claiming liquid protein compositions containing specific excipients.

Although the patent did not claim Denosumab, its sequence, or functional class, the explicit reference to the COM patent within the specification indicated a high potential for infringement of the client’s Denosumab formulation and was flagged to the client.

Read the full case study to see how GreyB’s patent intelligence protected a pharmaceutical company from a potential infringement dispute in a $3 billion market.

Request Full Case Study

Request Full Case Study

Download in PDF Format and read anytime. ​

The Researchers

Team Lead
A chemistry enthusiast who’s as sharp with pharmaceuticals as he is with his IP strategies.

Related Case Studies

Strengthening Health Safety and Material Integrity with Innovative Sterilization Solutions

Addressing the Challenge of Polymer Degradation During Sterilization The R&D team of a leading healthcare company was tasked with identifying innovative solutions that would preserve the essential properties of various

Invalidating a patent on the dosage regimen of a multimillion-dollar drug to help in generic drug entry

Value Delivered The prior art enabled the client to file an opposition against a threatening patent, resulting in the client’s entry into the market with their generic drug. Problems Solved

Revealing Hidden Antibody Formulation Risks via Composition of Matter Patent Linkage

Value Delivered The investigation enabled the client to uncover a hidden third-party patent that indirectly covered Denosumab formulations by referencing the COM patent. Identifying this risk early protected substantial investment

Developing Child-Resistant Packaging to Enhance Safety and Compliance

Urgent Need to Design Child-Resistant Packaging to Prevent Ingestion and Meet CPSC Standards The R&D team of a leading pharmaceutical company was tasked with developing innovative child-resistant packaging solutions to

How GreyB Strengthened Opposition Against a $500M Stem Cell Patent by Contacting a University Librarian

Value Delivered  GreyB helped the client establish compelling prior art by confirming the public availability of a key thesis with the head librarian of a university. This prior art targeted

Facing A Roadblock On Your Project?

Our Experts Are Here To Help.